Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 in Obese Subjects With T2DM
NCT01648153Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2012
- Primary completion
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of aletekitug in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Aug 2012; status: completed.
02
Drugs
aletekitug
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01648153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01648153.